Brokers Offer Predictions for Pharvaris FY2025 Earnings

Pharvaris (NASDAQ:PHVS) – Research analysts at Cantor Fitzgerald lowered their FY2025 EPS estimates for Pharvaris in a report released on Wednesday, May 14th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will earn ($3.41) per share for the year, down from their prior forecast of ($3.31). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Separately, JMP Securities upped their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Up 4.1%

Pharvaris stock opened at $16.56 on Friday. The company has a market cap of $865.92 million, a price-to-earnings ratio of -5.91 and a beta of -2.85. The firm’s fifty day moving average is $15.38 and its 200 day moving average is $17.63. Pharvaris has a 52-week low of $11.51 and a 52-week high of $25.50.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09).

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PHVS. Barclays PLC bought a new position in Pharvaris during the third quarter valued at $106,000. Palumbo Wealth Management LLC bought a new position in Pharvaris during the fourth quarter valued at $196,000. KLP Kapitalforvaltning AS bought a new position in Pharvaris during the fourth quarter valued at $111,000. JPMorgan Chase & Co. increased its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after acquiring an additional 2,847 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Pharvaris by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock valued at $735,000 after acquiring an additional 1,356 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.